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Introduction: The treatment of urinary tract infections has become more challenging due to 
the increasing frequency of multidrug-resistant Escherichia coli in human populations.
Objective: To characterize multidrug-resistant E. coli isolates causing community-acquired 
urinary tract infections in Cumaná, Venezuela, and associate possible risk factors for 
infection by extended-spectrum beta-lactamases (ESBL)-producing isolates.
Materials and methods: We included all the patients with urinary tract infections attending 
the urology outpatient consultation and emergency unit in the Hospital de Cumaná, Estado 
Sucre, Venezuela, from January through June, 2014. blaTEM, blaSHV and blaCTX-M genes 
detection was carried out by PCR.
Results: We found a high prevalence of multidrug-resistant E. coli (25.2%) with 20.4% 
of the isolates producing ESBL. The ESBL-producing isolates showed a high frequency 
(66.7%) of simultaneous resistance to trimethoprim-sulphamethoxazole, fluoroquinolones 
and aminoglycosides compared to non-producing isolates (2.4%). Of the resistant isolates, 
65.4% carried the blaTEM gene, 34.6% the blaCTX-M and 23.1% the blaSHV. The blaCTX-M 
genes detected belonged to the CTX-M-1 and CTX-M-2 groups. Plasmid transfer was 
demonstrated by in vitro conjugation in 17 of the 26 ESBL-producing isolates. All three 
genes detected were transferred to the transconjugants. Age over 60 years, complicated 
urinary tract infections and previous use of a catheter predisposed patients to infection by 
ESBL-producing E. coli.
Conclusions: The high frequency of multidrug-resistant ESBL-producing isolates should 
alert the regional health authorities to take measures to reduce the risk of outbreaks caused 
by these types of bacteria in the community.
Keywords: Escherichia coli; urologic diseases; beta-lactamases; rug resistance, bacterial; 
community-acquired infections.
Multirresistencia a medicamentos y factores de riesgo asociados con infecciones 
urinarias por Escherichia coli adquiridas en la comunidad, Venezuela
Introducción. El tratamiento de las infecciones urinarias constituye un reto creciente 
por el aumento de Escherichia coli proveniente de la comunidad multirresistente a los 
medicamentos.
Objetivo. Caracterizar aislamientos de E. coli multirresistente causantes de infecciones 
urinarias adquiridas en la comunidad en Cumaná, Venezuela, y detectar los posibles 
riesgos de infección por aislamientos productores de betalactamasas de espectro 
extendido (BLEE).
Materiales y métodos. Se incluyeron todos los pacientes atendidos en la consulta externa 
de urología y en urgencias del Hospital de Cumaná entre enero y junio de 2014 y que 
evidenciaban infecciones urinarias. La detección de los genes blaTEM, blaSHV y blaCTX-M se 
hizo mediante la reacción en cadena de la polimerasa (PCR). 
Resultados. Se encontró una alta prevalencia de E. coli multirresistente a los medicamentos 
(25,2 %), con 20,4 % de aislamientos productores de BLEE y una gran frecuencia de 
resistencia simultánea a trimetoprim-sulfametoxazol, fluoroquinolonas y aminoglucósidos 
(66,7 %) comparados con los no productores (2,4 %). En el 65,4 % de los aislamientos 
resistentes, se encontró el gen blaTEM; en 34,6 %, el blaCTX-M, y en 23,1 %, el blaSHV. Los 
genes blaCTX-M detectados pertenecían a los grupos CTX-M-1 y CTX-M-2. Se demostró la 
transferencia in vitro de plásmidos por conjugación en 17 de los 26 aislamientos productores 
de BLEE. Los tres tipos de genes detectados se transfirieron a los transconjugantes. La edad 
mayor de 60 años, las infecciones urinarias con complicaciones y el uso previo de catéter, 
predispusieron a la infección por cepas de E. coli productoras de BLEE.
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Conclusiones. La gran frecuencia de aislamientos multirresistentes productores de BLEE 
debería alertar a las autoridades sanitarias para tomar medidas que reduzcan el riesgo de 
epidemias causadas por este tipo de bacterias en la comunidad.
Palabras clave: Escherichia coli; enfermedades urológicas; beta-lactamasas; 
farmacorresistencia bacteriana; infecciones comunitarias adquiridas.
Urinary tract infections affect people of all ages and are one of the most 
frequently treated pathologies in primary healthcare centers. Although urinary 
infections can be caused by several species in the Enterobacteriaceae, most 
cases (both community and hospital-acquired) are produced by E. coli (1,2). 
Infection rates by extended-spectrum β-lactamases (ESBL)-producing E. coli 
have increased in the last 10 years in Latin America, with some regions showing 
prevalences of up to 32%. In addition, 11 to 25% of these ESBL-producing E. 
coli infections are now resistant to third generation cephalosporins including 
important rates of multidrug resistance, and only the antibiotics carbapenems, 
tigecycline and colistin are showing susceptibility rates >90% (3).
ESBL-producing strains are also often resistant to antibiotics of other 
classes (sulfonamides, aminoglycosides, quinolones) thus complicating 
treatment strategies. The screening of ESBL-producing bacteria by antibiotic 
susceptibility testing is challenging, hence detection of specific genes by 
PCR is commonly used for final confirmation. The most common ESBL are 
the SHV, TEM, and CTX-M types, and the association of these three types 
of enzymes with E. coli infections has been investigated in many studies. 
CTX-M-type enzymes have been shown to be the most prevalent ESBL (4) 
and have been associated with numerous outbreaks of infections both in 
hospitals and in the community, and particularly, along with the SHV and TEM 
types, in urinary E. coli strains isolated from nonhospital settings (5). This 
has resulted in a change in epidemiological patterns with ESBL-producing 
strains appearing outside the hospital environment, thus converting them into 
an emerging public health problem (2,6). The frequencies of ESBL found in 
South America rank amongst the highest in the world with CTX-M dominant 
possibly due to poorer social and economic situations, hospital overcrowding, 
lack of antimicrobial stewardship, excessive over-the-counter antibiotic usage, 
and under-supported infection control practices (6).
In Venezuela, there are several reports of infections by ESBL-producing 
Enterobacteriaceae species from Caracas (7), Cumaná (8), Ciudad Bolívar 
(9) and Mérida (10), and the reports from Ciudad Bolívar and Mérida also 
describe ESBL-producing isolates detected from communities. In this context 
and given the increasing probability of dissemination of ESBL-producing 
strains in the community, the aim of the present study was to characterize 
multidrug-resistant E. coli isolates causing community-acquired urinary 
tract infections and the risk factors associated with the presence of ESBL in 
Cumaná, Venezuela.
Materials and methods
Bacterial isolates and patients
 We evaluated a total of 103 E. coli isolates from patients attending 
the urology outpatient consultation and the emergency unit from January 
1st through June 30th, 2014, at the Hospital Universitario “Antonio Patricio 
de Alcalá” in Cumaná, Estado Sucre, Venezuela. Urine samples from 
patients from both genders (20 males and 83 females) and different 
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ages (ranging from 12 to 70 years) who showed urinary tract infection 
symptoms and indications for urine culture were examined for isolates. All 
patients were diagnosed with community-acquired urinary tract infection 
defined as previously suggested (11) as having abundant bacteria and 
polymorphonuclear leukocytes in the urine sample and positive urine culture 
with bacterial counts equal to or greater than 103 CFU/ml of urine when E. 
coli was identified. The urinary tract infections were classified as complicated 
or uncomplicated according to the guidelines established by the Infectious 
Diseases Society of America (12).
A community-acquired infection was defined according to the criteria 
proposed by Friedman, et al. (13), differentiating it from healthcare-associated 
infections and hospital-acquired infections, like an infection present at the 
moment of the consultation and when patients had not received any of the 
following: intravenous therapy at home, wound care or specialized nursing 
care administered by a healthcare agency, close family or friends, and self-
administered intravenous medical therapy in the 30 days before the infection 
as well as those patients that did not attend a hospital or hemodialysis clinic, 
or received intravenous chemotherapy in the previous 30 days, or had been 
hospitalized in an acute care hospital for two or more days in the previous 90 
days, or resided in a nursing home or long-term care facility.
Microbial susceptibility tests and detection of ESBL
Antimicrobial susceptibility and interpretation were evaluated using 
the disk diffusion susceptibility test according to the Clinical Laboratory 
Standards Institute (14). The antimicrobials tested (Oxoid Ltd., UK) were 
ampicillin (10 µg), cefalotin (30 µg), cefoxitin (30 µg), cefotaxime (30 µg), 
ceftazidime (30 µg), cefepime (30 µg), aztreonam (30 µg), piperacillin-
tazobactam (100/10 µg), imipenem (10 µg), meropenem (30 µg), 
ampiciliin-sulbactam (10/10 µg) amoxicillin-clavulanic acid (2:1) (30 µg), 
nalidixic acid (30 µg), ciprofloxacin (5 µg), amikacin (30 µg), tobramycin 
(10 µg) and trimethropim-sulfamethoxazole (25 µg). 
ESBL phenotypes were confirmed using the combined disc method (14) 
using E. coli ATCC 25922 and K. pneumoniae ATCC 700603 as the control 
strains. Multidrug resistance was defined as those isolates that showed 
resistance to ≥1 agents in ≥3 antimicrobial categories according to the 
consensus of a group of international experts (15).
Detection of the genes coding for β-lactamases
DNA was isolated by extraction using the Wizard Genomic purification 
kit™ (Promega). Resistant genes were identified by means of a PCR assay 
for blaTEM, blaSHV and blaCTX-M using the primers described elsewhere (16-18). 
The PCR products were electrophoresed in 2% agarose gel and stained with 
GelRed Nucleic Acid Stain™ (Biotium). A 100 bp DNA ladder (Fermentas, 
Lithuania) was used as the molecular weight marker.
Transfer of resistance
 Conjugation assays were done in a solid medium using E. coli j62-
2 (resistant to rifampicin, CVCM 131) as the recipient (7). The clinical 
and recipient strains were grown separately in Luria-Bertani broth (Hardy 
Diagnostics, Santa Maria, CA, USA) at 37°C for 18 hours, and then mixed in 
a ratio of 1:4 (clinical isolates: recipient). Transconjugants were selected on 
MacConkey agar containing 100 µg rifampicin and 2 µg cefalotin.
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Differentiation of the CTX-M group by PCR-RFLP
Restriction enzyme digestion was carried out according to Mahboobeh 
(19).The members of the CTX-M group were identified according to the 
fragments generated by double digestion by the PstI and PvuII enzymes. 
E. coli 2944NR was used as an RFLP positive control since it contains 
aCTX-M-1 type β-lactamase while E. coli J62-2 was used as a negative 
control. The RFLP products were observed in a 2% agarose gel containing 
GelRedNucleic Acid Stain™ (Biotium).
Statistical analyses
The risk factors considered in this study were: Nasogastric tube use, Foley 
catheter use, chronic kidney disease, cerebral vascular accident, bedridden, 
immunosuppression treatment, pregnancy, presence of any functional or 
structural urinary abnormality, diagnosis of a urinary tract infection within one 
year, antimicrobial treatment within three months, hospitalization within the 
previous three months but not within the previous 30 days, diabetes, and age 
over 60.
The risk factors associated with infection by an ESBL-producing E. coli 
isolate were determined firstly by using a binary logistic regression for each 
variable followed by multivariate analysis for those variables showing best 
relevance, in which the variables were considered as predictors of ESBL. 
The analysis was performed using a stepwise selection of variables, 
and the area under the ROC curve was calculated to determine the model’s 
predictive ability. The statistical analyses were carried out using the statistical 
package for the social sciences (SPSS™, version 18, IBM Corporation).
Ethical aspects
The patients gave their written consent after they were informed of 
the risks and benefits of participating in the study and had answered an 
epidemiological questionnaire. 
The treatment of the patients, the analysis of the isolates, and the 
information generated were conducted according to the bioethical 
and biosafety guidelines set out by the Comisión de Ética, Bioética y 
Biodiversidad of the Instituto de Investigaciones en Biomedicina y Ciencias 
Aplicadas «Dra. Susan Tai” at the Universidad de Oriente.
Results
The E. coli isolates (n=103) evaluated in this study showed high rates 
of resistance for the antimicrobials frequently used to treat patients with 
urinary infections, such as ampicillin (96.1%), cefalotin (59.4%) and 
ampicillin-sulbactam (24.8%), amoxicillin-clavulanate (25.7%), trimethoprim-
sulfamethoxazole (39.6%) and ciprofloxacin (29.7%). 
The isolates from the uncomplicated urinary tract infections (30.1%) 
showed significantly lower resistance compared to those from complicated 
urinary tract infections (figure 1).
A total of 26 (25.2%) isolates were multidrug resistant (table 1), of which 21 
(20.4%) showed production of ESBL. Of the 26 multidrug resistant isolates, 18 
showed resistance to six or more antimicrobial categories, and the categories 
most associated with resistance were penicillins, cephalosporins, both with 
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Figure 1. Frequency of resistant Escherichia coli isolates from patients with community-acquired 
urinary tract infections
AMP: Ampicillin; CF: Cefalotin; FOX: Cefoxitin; AMC: Amoxacillin-clavulanic acid; TZP: Piperacillin-tazobactam; 
SAM: Ampicillin-sulbactam; CAZ: Ceftazidime; CTX: Cefotaxime; FEP: Cefepime; ATM: Aztreonam; IMP: imipenem; 
MEM: meropenem; CIP: Ciprofloxacin; LEVO: Levofloxacin; AK: Amikacin; STX: Trimethoprim-sulfamethoxazole
Note: Isolates with intermediate resistance were classified as resistant.
and without extended-spectrum, and folate pathway inhibitors (table 1). ESBL-
producing isolates also showed a high frequency (66.7%) of simultaneous 
resistance to trimethoprim-sulphamethoxazole, fluoroquinolones and 
aminoglycosides compared to non-producing isolates (2.4%).
The blaTEM gene was found in 17 isolates (65.4%) while blaCTX-M was 
detected in nine isolates (34.6%) and blaSHV in six isolates (23.1%). The blaTEM 
and blaSHV genes were found in E. coli isolates, ESBL-producing or not, while 
blaCTX-M was only found in ESBL-producing isolates. More than one gene 
was amplified in seven isolates: The most frequent combination was blaTEM + 
blaCTX-M (four isolates), and a three-gene combination was found in two ESBL 
producing isolates (table 1). The RFLP results revealed that five of the blaCTX-M 
genes were identified as belonging to the CTX-M-2 group and four to the 
CTX-M-1 group (figure 2).
Of the 26 multidrug resistant isolates resistant to third generation 
cephalosporins and subjected to in vitro bacterial conjugation, only 17 
were able to transfer plasmids with resistance genes at a mean transfer 
rate of 10-7clinical isolates-transconjugant. Phenotypic analysis of the 
transconjugants demonstrated that part of the resistance pattern present in 
the clinical isolates was also observed in the transconjugants (table 1). All 
of the blaCTX-M genes were transferred to the transconjugant strain from the 
clinical isolates while only 64.7% (11/17) of the blaTEMgene and 33.3% (2/6) of 
the blaSHV were transferred (table 1). In the transconjugants of the two clinical 
isolates containing the three genes (204 and 339), the blaSHV gene was not 
transferred. These results demonstrate the transmissibility of bla genes to 
other E. coli strains. 
When analyzing the risk factors for ESBL-producing E. coli, we found 
that an age over 60 years, complicated urinary tract infection, and urinary 
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Table 1. Phenotypic and molecular characteristics of multidrug resistant Escherichia coli isolates. Here we show the DDST phenotypes of the bacterial 
isolates from patients with community-acquired urinary tract infections and their transconjugants, when appropriate, as well as the genes detected by PCR.
ESBL: Extended-spectrum β-lactamases; AMP: Ampicillin; CF: Cefalotin; AMC: Amoxacillin-clavulanic acid; FOX: Cefoxitin; CAZ: Ceftazidime; CTX: Cefotaxime; 
ATM: Aztreonam; SAM: Ampicillin-sulbactam; TZP: Piperacillin-tazobactam; FEP: Cefepime; CIP: Ciprofloxacin; LEVO: Levofloxacin; AK: Amikacin; TOB: Tobramycin; 
STX: Trimethoprim-sulfamethoxazole
Isolates ESBL Resistance Bla genes Resistance in transconjugants
Bla genes 
transferred
EC14 + AMP, CF, CAZ, CTX, STX blaTEM
EC33 - AMP, CF, FOX, CTX, ATM, CIP, LEVO, STX blaSHV 
EC37 - AMP, CF, CTX, CIP, STX -
EC49 - AMP, CF, AMC, CAZ, CTX, ATM, CIP, LEVO, AK, 
TOB, STX,
blaTEM 
EC95 + AMP, CF, AMC, CAZ, CTX, CIP, LEVO, STX blaSHV 
EC190 - AMP, CF, CAZ, NAL, CIP, LEVO, STX blaTEM 
EC305 - AMP, CF, AMC, CTX, ATM, SAM, CIP, LEVO, 
AK, TOB, STX
blaTEM 
EC372 + AMP, CF, CAZ, CTX, FEP, CIP, STX blaTEM 
EC918 + AMP, CF, CAZ, CTX, FEP, CIP, LEVO blaTEM 
EC16 + AMP, CF, CAZ, CTX, SAM, STX blaTEM AMP, CF, CAZ, CTX, STX blaTEM
EC30 + AMP, CF, CTX, SAM, CIP, TOB, STX blaTEM, blaCTX-M AMP, CF, CTX, TOB, STX blaTEM, blaCTX-M
EC61 + AMP, CF, AMC, FOX, CAZ, CTX, SAM, CIP, 
LEVO, AK, TOB, STX
blaTEM, blaCTX-M AMP, CF, CTX, AK, TOB, STX blaTEM, blaCTX-M
EC78 + AMP, CF, CTX, SAM, CIP, LEVO, TOB, STX blaTEM AMP, CF, CTX, TOB, STX blaTEM
EC84 + AMP, CF, CTX, SAM, CIP, TOB, STX blaTEM AMP, CF, CTX, STX blaTEM
EC123 + AMP, CF, CAZ, CTX, FEP CIP, LEVO, TOB, STX blaSHV AMP, CF, CAZ, CTX, FEP, TOB, STX blaSHV 
EC204 + AMP, CF, AMC, CTX, ATM, CIP, LEVO, TOB, 
STX
blaTEM, blaSHV, blaCTX-M AMP, CF, CTX, TOB, STX blaTEM, blaCTX-M
EC339 + AMP, CF, AMC, FOX, CAZ, CTX, ATM, SAM, 
CIP, LEVO, AK, TOB, STX
blaTEM, blaSHV, blaCTX-M AMP, CF, CAZ, CTX, ATM, AK, TOB, STX blaTEM, blaCTX-M
EC347 + AMP, CF, AMC, CAZ, CTX, FEP, SAM, CIP, 
LEVO, AK, TOB
blaCTX-M AMP, CF, CAZ, CTX, FEP, NAL, CIP, AK, 
TOB
blaCTX-M
EC348 + AMP, CF, AMC, CAZ, CTX, FEP, SAM, CIP, 
LEVO, TOB, STX
blaTEM, blaSHV AMP, CF, CAZ, CTX, FEP, TOB, STX blaTEM, blaSHV
EC385 + AMP, CF, AMC, FOX, CAZ, CTX, ATM, SAM, 
CIP, LEV, TOB
- AMP, CF, CAZ, CTX, TOB -
EC514 + AMP, CF, AMC, FOX, CAZ, CTX, ATM, SAM, 
CIP, LEVO, TOB, STX
blaCTX-M AMP, CF, CAZ, CTX, ATM, TOB, STX blaCTX-M
EC779 + AMP, CF, CAZ, CIP, LEVO, STX - AMP, CF, CAZ -
EC868 + AMP, CF, AMC, CTX, CIP, LEVO, STX blaTEM, blaCTX-M AMP, CF, AMC, CTX blaTEM, blaCTX-M
EC876 + AMP, CF, CAZ, CTX, PTZ, FEP, CIP, LEVO, AK, 
TOB, STX
blaTEM AMP, CF, CAZ, CTX, FEP, AK, TOB, STX blaTEM 
EC926 + AMP, CF, AMC, CAZ, CTX, ATM, SAM, CIP, 
LEVO, AK, TOB, STX
blaTEM, blaCTX-M AMP, CF, CAZ, CTX, NAL, CIP, AK, TOB, 
STX
blaTEM, blaCTX-M
EC983 + AMP, CF, AMC, CAZ, CTX, ATM, FEP, CIP, 
LEVO, AK, TOB, STX
blaCTX-M AMP, CF, CAZ, CTX, ATM, FEP, AK, TOB, 
STX
blaCTX-M
catheterization (more than 30 days previous to the infection) predisposed 
patients to an infection by a multidrug resistant/ESBL-producing E. coli strain 
(table 2) with relative risks (RR) 3.1 (95% CI: 1.5-6.4), 4.1 (95% CI: 1.1-
16.5),and 3.3 (95% CI: 1.6-6.8) times higher, respectively, for patients with 
those conditions compared to those without them. 
Other risk factors, such as nasogastric tube use, cerebral vascular 
accident, bedridden patients, immunosuppression treatment, pregnancy, the 
presence of a structural urinary abnormality, and hospitalization within the 
previous three months were not analyzed since no ESBL-producing isolate 
was found in any of the patients showing these conditions.
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Table 2. Epidemiological and clinical variables associated with ESBL-producing Escherichia coli
ESBL: Extended spectrum β-lactamases; RR: Relative risk; CI: Confidence interval
* Statistically significant
a Within three months
b First line β-lactams: AMP, SAM, and CF
c Extended spectrum cephalosporins: 3rd and 4th generation cephalosporins and monobactams (ATM)
Risk factors n
ESBL +
(n=21)
ESBL -
(n=82)
p
RR
(95% CI)
Male gender 20 9 11 0.962
Age >60 years 20 9 11 0.002* 3.1
(1.5-6.4)
Complicated urinary tract infection 72 19 53 0.048 4.1
(1.1-16.5)
Recurrent urinary tract infection 38 5 33 0.183
Previous (30 days) urinary catheterization 11 6 5 0.001* 3.3
(1.6-6.8)
Previous empiric treatment with first line beta-lactamsa,b 35 13 28 0.134
Treatment with extended spectrum cephalosporinsa,c 28 5 23 0.313
Renal lithiasis 32 7 25 0.603
Renal impairment 12 2 10 0.493
Diabetes 29 9 20 0.389
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Figure 2. Digestion profile of the blaCTX-M gene detected in Escherichia coli isolated from patients with 
community-acquired urinary infections 
M: Molecular weight marker (1 kb Invitrogen); C+: Undigested blaCTX-M-2 fragment; C+1: Control blaCTX-M-1, strain 
2944NR; C+2: Control blaCTX-M-2 Kp 22; lines 5-13: Isolates of Escherichia coli containing the blaCTX-M gene 
Of the 20 male patients with complicated urinary tract infections, seven 
were aged over 60 with functional problems due to their prostate or kidneys 
and frequently attended the urology consultation for their control. All seven 
patients had urinary tract infections caused by ESBL-producing isolates. 
Of the 83 female patients with urinary tract infections, 53 were classified as 
complicated due to any of the abovementioned factors but with recurrent 
urinary tract infections within a year being the most frequent condition.
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Discussion
The resistance of E. coli isolates from complicated urinary tract infections 
to many of the antimicrobials tested here indicates that treatment should only 
be given after susceptibility testing. High resistant rates to third-generation 
cephalosporins and aztreonam of clinical isolates of another bacteria, K. 
pneumoniae, have also been found in a previous study undertaken in Cumaná 
(12). The relatively high frequency of multidrug resistant E. coli found in the 
community and the high proportion of isolates showing resistance to ≥6 
antimicrobials indicates the need to revise the treatment guidelines for urinary 
tract infections in Venezuela. A significant increase in the prevalence of 
multidrug resistant E. coli has also been reported in the US with rates raising 
from 9.1% in 2001 to 17.0% in 2010 (20) and resistance to three, four or five 
antimicrobial agents. In the same study, widespread resistance was observed 
for trimethoprim-sulfamethoxazole (62.6%, 88.6%, and 97.9%, respectively) 
and ciprofloxacin (48.9%, 84.3%, and 98.2%, respectively).
Uncomplicated community-acquired urinary tract infections are normally 
treated empirically without undertaking a urine culture or an antibiogram 
unless they recur repeatedly (21). Our findings, however, demonstrate the 
importance of monitoring this empirical use of antimicrobials at a community 
level as recommended by the Infectious Diseases Society of America in order 
to select an appropriate empirical treatment (22).
β-lactam antibiotics are commonly the first choice of treatment against 
many microorganisms including uropathogens. Nevertheless, in recent years 
there has been a progressive increase in the frequency of E. coli strains from 
outpatients that characteristically show reduced susceptibility to penicillins 
and third generation cephalosporins due to the production of ESBL (23). This 
is now considered an emergent problem at the community level especially 
as changes in epidemiological patterns have been observed: While SHV 
and TEM have been shown to be the most prevalent enzymes in nosocomial 
strains, CTX-M is reported as predominant in community-acquired strains (24). 
In this study, phenotypic characterization revealed that an important fraction 
of the isolates studied produced ESBLs. Here, the blaTEM gene was the most 
prevalent ESBL gene indicating the possible circulation of TEM-type ESBLs in 
strains from the community that have not been detected in nosocomial strains from 
the Hospital General de Cumaná (12). We also found variations in the antibiotic 
resistance of isolates containing only blaTEM, which may suggest the presence of 
clavulanic-acid inhibited ESBLs not characterized in this study, or the presence 
of other blaTEM type genes. The non-ESBL-producing isolates that did contain the 
blaTEM gene are probably TEM-1 that confers resistance to penicillins and first-
generation cephalosporins. Resistance to third-generation cephalosporins could 
then be due to other resistance mechanisms, for example, OXA-type enzymes 
which have been identified from some E. coli strains isolated from patients with 
community-acquired urinary tract infections in India (25). The blaSHV gene has been 
found to be less frequent in community-based strains than blaTEM and blaCTX-M (26).
The identification of the specific CTX-M enzyme type from the susceptibility 
pattern proved to be difficult due to the overlapping of the ceftazidime and 
cefotaxime phenotypes and the fact that several genes were present. The 
wide dissemination of CTX-Ms around the world has been referred to as 
the “CTX-M pandemic” since this enzyme is the most common β-lactamase 
carried by the Enterobacteriaceae that cause community onset urinary tract 
infections as shown in reports from different continents (2,24,27-31).
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In Venezuela, there have been very few reports that identify the type of bla 
genes found in bacterial strains causing urinary infections. The CTX-M-32 enzyme 
(CTX-M-1) was identified in an E. coli strain isolated from a patient with diabetes 
from the Mérida state who was also suffering from a community-acquired urinary 
tract infection, which is the first report of this variant in South America (32).
It is important to note that some CTX-M enzymes are associated with 
specific countries: CTX-M-9 in Spain; CTX-M-1 in Italy and the United 
Kingdom, and CTX-M-2 in Israel, Japan, and most South American countries 
(24,33). In contrast, variants such as CTX-M-15 (CTX-M-1), which originated 
from the Asp240Gly substitution in CTX-M-3 and CTX-M-14 have been 
detected all over the world (24,34). The seasonal appearance and spread of 
these enzymes in different habitats may partially explain their epidemiology. 
The use of antimicrobials and other risk factors in different regions, as well 
as the characteristics of different geographical compartments, may have 
contributed to the current situation surrounding CTX-M.
The in vitro bacterial conjugation assays demonstrated that the genes 
coding for ESBL are localized in transferable plasmids which also carry other 
resistance determinants affecting antimicrobials, such as aminoglycosides, 
trimethoprim-sulfamethoxazole, and quinolones. Furthermore, the transfer 
of resistance to ciprofloxacin and nalidixic acid indicates that these strains 
contain a resistance mechanism against this group of antimicrobials that 
can disseminate horizontally as well as vertically. In India, 94% of the CTX-
M-producing isolates were able to transfer their genes by conjugation with 
plasmids ranging in size from 120 to 272 kbp and half of these plasmids 
also carried the TEM-1 gene (25). This dissemination of ESBL in conjugative 
plasmids increases the possibility of an accelerated rate of proliferation (2).
Few studies have evaluated risk factors for community-onset ESBL infections 
and some of the studies previously undertaken in the U.S.A. were conducted 
prior to the emergence of community-wide multidrug-resistant E. coli (35). 
Here we identified age over 60 years, complicated urinary tract infections, and 
urinary catheterization as risk factors for infection with ESBL-producing E. coli 
strains. Other studies have also shown older age (35-40), urinary catheterization 
(36,37,39) and complicated urinary tract infections (40) as factors that increase 
the risk of acquiring a urinary tract infection by multidrug resistant bacteria.
In conclusion, our results reveal the presence of multidrug resistant 
isolates that cause community-acquired urinary infections. This is of great 
epidemiological importance and requires the intervention of the health authorities 
in the region to prevent further dissemination of these types of strains.
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